Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMAGINE study of brolucizumab imaging biomarkers in wet age-related macular degeneration
2020-002452-20Phase 4Completed
- Sponsor
- Novartis
- Start
- May 2021
- Modality
- scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of brolucizumab in exudative macular degeneration, sponsored by Novartis. Primary endpoint: Early predictive factors of fluid-free response. Started May 2021; status: completed.
02
Drugs
brolucizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2020-002452-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002452-20.